Literature DB >> 21903958

Mild stroke and rapidly improving symptoms: it's not always a happy ending.

Clotilde Balucani, Steven R Levine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21903958      PMCID： PMC3410646          DOI： 10.1161/STROKEAHA.111.628701

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  26 in total

1.  Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.

Authors: 
Journal:  Ann Emerg Med       Date:  2005-09       Impact factor: 5.721

2.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility.

Authors:  P A Barber; J Zhang; A M Demchuk; M D Hill; A M Buchan
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

3.  Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke.

Authors:  Eric E Smith; Abdul R Abdullah; Iva Petkovska; Eric Rosenthal; Walter J Koroshetz; Lee H Schwamm
Journal:  Stroke       Date:  2005-10-06       Impact factor: 7.914

4.  Early MRI and outcomes of untreated patients with mild or improving ischemic stroke.

Authors:  V Rajajee; C Kidwell; S Starkman; B Ovbiagele; J R Alger; P Villablanca; F Vinuela; G Duckwiler; R Jahan; A Fredieu; S Suzuki; J L Saver
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

5.  Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.

Authors:  Maaike Dirks; Louis W Niessen; Peter J Koudstaal; Cees L Franke; Robert J van Oostenbrugge; Diederik W J Dippel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-01       Impact factor: 10.154

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004.

Authors:  H Christian Schumacher; Brian T Bateman; Bernadette Boden-Albala; Mitchell F Berman; J P Mohr; Ralph L Sacco; John Pile-Spellman
Journal:  Ann Emerg Med       Date:  2007-05-03       Impact factor: 5.721

8.  Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.

Authors:  Dawn Kleindorfer; Brett Kissela; Alex Schneider; Daniel Woo; Jane Khoury; Rosemary Miller; Kathleen Alwell; James Gebel; Jerzy Szaflarski; Arthur Pancioli; Edward Jauch; Charles Moomaw; Rakesh Shukla; Joseph P Broderick
Journal:  Stroke       Date:  2004-01-22       Impact factor: 7.914

9.  Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Authors:  Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks
Journal:  Circulation       Date:  2007-05-22       Impact factor: 29.690

10.  Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms.

Authors:  Christian R Baumann; Ralf W Baumgartner; Joubin Gandjour; Hans-Christian von Büdingen; Adrian M Siegel; Dimitrios Georgiadis
Journal:  Stroke       Date:  2006-03-23       Impact factor: 7.914
View more
  8 in total

1.  To treat or not to treat? Pilot survey for minor and rapidly improving stroke.

Authors:  Clotilde Balucani; Riccardo Bianchi; Edward Feldmann; Jeremy Weedon; Dmitri Kolychev; Steven R Levine
Journal:  Stroke       Date:  2015-01-20       Impact factor: 7.914

Review 2.  Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide.

Authors:  Bart M Demaerschalk
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

3.  Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke.

Authors:  Jinju Guk; Dongwoo Chae; Hankil Son; Joonsang Yoo; Ji Hoe Heo; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2018-08-21       Impact factor: 4.335

Review 4.  Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.

Authors:  Steven R Levine; Pooja Khatri; Joseph P Broderick; James C Grotta; Scott E Kasner; Doojin Kim; Brett C Meyer; Peter Panagos; Jose Romano; Phillip Scott
Journal:  Stroke       Date:  2013-07-11       Impact factor: 7.914

5.  Safety and outcome of thrombolysis in mild stroke: a meta-analysis.

Authors:  Lei Shi; Min Zhang; Hengfang Liu; Bo Song; Changdong Song; Dandan Song; Yuming Xu
Journal:  Med Sci Monit       Date:  2014-11-02

6.  Reasons and evolution of non-thrombolysis in acute ischaemic stroke.

Authors:  T Reiff; P Michel
Journal:  Emerg Med J       Date:  2016-10-25       Impact factor: 2.740

7.  Reperfusion therapy for minor stroke: A systematic review and meta-analysis.

Authors:  Lihuan Lan; Xiaoming Rong; Xiangpen Li; Xiaoni Zhang; Jingrui Pan; Hongxuan Wang; Qingyu Shen; Ying Peng
Journal:  Brain Behav       Date:  2019-09-18       Impact factor: 2.708

8.  Progression of stroke deficits in patients presenting with mild symptoms: The underlying etiology determines outcome.

Authors:  Naveed Akhtar; Saadat Kamran; Hisham Elkhider; Soha Al-Makki; Noha Mhjob; Lubna ElShiekh; Hassan AlHussain; Musab Ali; Rola Khodair; Faisal Wadiwala; Abdul Salam; Dirk Deleu; Reny Francis; Ashfaq Shuaib
Journal:  PLoS One       Date:  2020-04-24       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.